Eva Pérez‐Pampín

Author

Eva Pérez‐Pampín

Complejo Hospitalario Universitario de Santiago ORCID

Also Known As

Ariana Montes, Carlos Rodriguez-Lozano, E Perez-Pampin, E Pérez Pampín, E Pérez-Pampin, E Pérez-Pampín, E. Perez-Pampin, E. Perez-Pampín, E. Pérez Pampín, E. Pérez-Pampin

178

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Complejo Hospitalario Universitario de Santiago Instituto de Investigación Sanitaria de Santiago Universidade de Santiago de Compostela Hospital Universitario Virgen Macarena Bellvitge University Hospital

About

Eva Pérez‐Pampín is an author at Complejo Hospitalario Universitario de Santiago specializing in medicine, autoimmune disease, and rheumatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	16	1.2K
2	Immunology	10	10	595
3	Epidemiology	2	2	64
4	Public Health	1	1	35
5	Allergy	1	1	35

Eva Pérez‐Pampín

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial J.V. Pérez-Moreiras, Juan J. Gómez‐Reino, José Ramón Maneiro, American Journal of Ophthalmology MedicineRandomized Clinical TrialDermatology	2018	277
All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists Loreto Carmona, M.Á. Descalzo, Eva Pérez‐Pampín, Annals of the Rheumatic Diseases	2007	228
Assessment of global DNA methylation in peripheral blood cell subpopulations of early rheumatoid arthritis before and after methotrexate María C. de Andrés, Eva Pérez‐Pampín, Manuel Calaza, Arthritis Research & Therapy Rheumatoid DisorderRheumatologyChromatinAutoimmune DiseaseMedicine	2015	144
Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients J. Loricera, Ricardo Blanco, José L. Hernández, Seminars in Arthritis and Rheumatism RheumatologyAutoimmune DiseaseVasculitisImmunologyMulticenter Open-label Study	2014	132
Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice Monica Calderón-Goercke, J. Loricera, Vicente Aldasoro, Seminars in Arthritis and Rheumatism RheumatologyAutoimmune DiseaseVasculitisOpen-label Multicenter StudyImmunology	2019	105
Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors Marian Suarez-Gestal, Manuel Calaza, Rebeca Dieguez‐Gonzalez, Arthritis & Rheumatism	2009	59
Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-κB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility Rebeca Dieguez‐Gonzalez, Manuel Calaza, Eva Pérez‐Pampín, Arthritis Research & Therapy	2009	59
Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis Aida Ferreiro-Iglesias, Ariana Montes, Eva Pérez‐Pampín, The Pharmacogenomics Journal InflammationRheumatologyRheumatoid DisorderAutoimmune DiseaseMedicine	2015	47
A CTLA‐4 polymorphism associated with susceptibility to systemic lupus erythematosus L. Fernández‐Blanco, Eva Pérez‐Pampín, Juan J. Gómez‐Reino, Arthritis & Rheumatism ImmunogeneticsAutoimmune DiseaseSystemic Lupus ErythematosusSystemic Lupus Erythematosus TreatmentLupus	2004	46
Genetic variation in the nuclear factor κB pathway in relation to susceptibility to rheumatoid arthritis Rebeca Dieguez‐Gonzalez, Servet Akar, Manuel Calaza, Annals of the Rheumatic Diseases	2008	42

Page 1